Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Faculty Opinions recommendation of Empagliflozin and progression of kidney disease in type 2 diabetes. — Giuseppe Remuzzi | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Faculty Opinions recommendation of Empagliflozin and progression of kidney disease in type 2 diabetes.
Shared by
Giuseppe Remuzzi
Faculty Opinions recommendation of Empagliflozin and progression of kidney disease in type 2 diabetes.
Dataset
en
Authors
Giuseppe Remuzzi
AS
Arrigo Schieppati
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Dataset
Faculty Opinions recommendation of Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Giuseppe Remuzzi
,
Amantia Imeraj
Dataset
Faculty Opinions recommendation of Volume progression in polycystic kidney disease.
Giuseppe Remuzzi
Article
2021
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes
Piero Ruggenenti
,
Bettina J. Kraus
,
Silvio E. Inzucchi
,
Bernard Zinman
,
Stefan Hantel
,
Michaela Mattheus
,
Maximilian von Eynatten
,
Giuseppe Remuzzi
,
Audrey Koitka‐Weber
,
Christoph Wanner
Dataset
Faculty Opinions recommendation of Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
Giuseppe Remuzzi
,
Arrigo Schieppati
Dataset
Faculty Opinions recommendation of Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.
Giuseppe Remuzzi
,
Arrigo Schieppati
.webp)
Discussion(0)
No comments yet. Be the first to comment.